Trial Profile
A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab-Paclitaxel or Ixabepilone With or Without Bevacizumab as First[95]-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs Ixabepilone (Primary) ; Paclitaxel (Primary) ; Bevacizumab
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms Alliance
- 06 Jun 2023 Results of post-hoc analysis assessing Association of tumor infiltrating lymphocyte quantity with survival in patients with metastatic breast cancer receiving microtubule-targeting agents, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 04 Aug 2022 Status changed from active, no longer recruiting to completed.
- 01 Feb 2022 Results from TARGET study and four (CALGB/Alliance) clinical trials identifying predictive biomarkers of hypertension induced by these drugs using a discovery-replication approach published in the Pharmacogenomics Journal